L
arge epidemiological studies have shown that lipidlowering therapy with HMG-CoA reductase inhibitors leads to a significant reduction in cardiac mortality and morbidity. [1] [2] [3] Angiographic studies demonstrated a disparity between the decrease in cardiac events and the extent of regression of coronary artery lesions. 4 These observations suggest that mechanisms other than regression of atherosclerosis are operational in the reduction of coronary events with lipid-lowering therapy. It has been postulated that the clinical benefit is mediated by the stabilization of rupture-prone plaques and the enhancement of endothelial function. 5, 6 Other possible mechanisms include reduced thrombotic potential, cytotoxicity, and inflammatory response. 7 Recent studies have shown beneficial effects of lipidlowering therapy on the response of epicardial coronary arteries to acetylcholine within 6 to 12 months after initiation of therapy. 5, 6 Gould et al 8 evaluated relative perfusion in patients with coronary artery disease (CAD) using semiquantitative analysis of 13 N-labeled ammonia PET images and found a significant improvement in stress-induced defect size and perfusion abnormalities after 3 months of lipid-lowering therapy.
Tracer kinetic modeling allows quantitative analysis of regional blood flow and calculation of coronary flow reserve (CFR) with 13 N-labeled ammonia PET in conjunction with adenosine, which has been demonstrated to be an accurate and reproducible technique. 9 -13 Additionally, impaired CFR is one of the earliest abnormalities associated with CAD and thus can be used as a sensitive parameter to monitor the effects of risk factor manipulation. 10 The purpose of this study was to assess the temporal changes of myocardial flow and flow reserve as a marker of microcirculation in response to long-term pharmacological therapy with fluvastatin in patients with modest CAD and hypercholesterolemia.
Methods

Study Population
Patients undergoing elective coronary arteriography for evaluation of chest pain were considered eligible if angiography documented multivessel CAD with atherosclerotic stenoses exceeding 30% of lumen diameter in Ͼ1 vascular territory and if LDL cholesterol level exceeded 160 mg/dL. Exclusion criteria included need for revascularization procedure, proximal stenosis of Ͼ75%, coronary angio-plasty or myocardial infarction within the past 6 months, history of coronary bypass surgery, left ventricular ejection fraction Ͻ40%, severe arterial hypertension (systolic and diastolic blood pressures Ͼ160 mm Hg and Ͼ90 mm Hg, respectively), insulin-dependent diabetes mellitus, treatment with ACE inhibitors, prior lipidlowering therapy, and severe concomitant illness.
Study Protocol
Myocardial perfusion was measured with dynamic 13 N-labeled ammonia PET under rest and stress conditions at baseline and at 2 and 6 months after the initiation of therapy. A symptom-limited bicycle test was performed at the time of study entry and at 6 months (study protocol is outlined in Figure 1 ). Anginal symptoms were reported with the use of a questionnaire at baseline and at 6 months and classified according to the Canadian Cardiovascular Society (CCS) classification system. 14 Patients continued taking their concomitant medications during the entire study interval except on the day of PET studies. After baseline PET investigation, 40 mg of fluvastatin (Cranoc, Astra GmbH) was administered once daily. Patients were scheduled to visit the clinic every 4 weeks, and lipid serum concentrations were evaluated with the patient fasting for 12 hours overnight. Because a reduction of LDL cholesterol of Ͼ30% was the goal, the fluvastatin dose was increased to 60 or 80 mg/d after 1 month of medication if LDL cholesterol was not reduced by Ͼ30%.
The study protocol was approved by the Ethics Committee of the Technische Universität München. Informed consent was obtained before each patient was enrolled into the study.
Laboratory Methods
Total cholesterol and triglycerides were measured by enzymatic methods (Boehringer Mannheim). Serum HDL cholesterol concentration was measured enzymatically from the serum supernatant after precipitation of chylomicrons, VLDLs, and LDLs with phosphotungstic acid and magnesium ions. LDL cholesterol was calculated from the difference between the serum total cholesterol and the cholesterol in the supernatant after precipitation with polyvinyl sulfate.
PET Imaging Protocol
All patients fasted for Ն12 hours. Vasoactive medications were discontinued for Ն24 hours before the PET study. The ECG was continuously monitored. Systolic and diastolic arm blood pressures were obtained at 1-minute intervals. Rate-pressure product (RPP) was calculated as heart rate times systolic blood pressure divided by 100.
Dynamic PET measurements were performed with a whole-body scanner (CTI/ECAT 951R/31; Siemens/CTI). After a transmission scan for attenuation correction, 20 mCi of 13 N-labeled ammonia was administered as a bolus over 30 seconds by an infusion pump. The dynamic PET data acquisition consisted of varying frame durations (12ϫ10 seconds, 6ϫ30 seconds, and 3ϫ300 seconds). For the stress study, adenosine was infused at a dose of 0.14 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 over 5 minutes.
13 N-labeled ammonia was administered in a similar fashion as in the baseline study during the third minute of the adenosine infusion.
After the data were reconstructed with a Hanning filter, each data set was reoriented to 12 short-axis views of the heart by use of a SUN workstation (SUN Microsystems, Inc). Further analysis comprised automated region definition, motion correction, and calculation of regional myocardial blood flow in 3 regions of interest representing the vascular territories of epicardial arteries. 11, 12 We calculated coronary resistance at rest by dividing the mean blood pressure [(systolic blood pressureϩdiastolic blood pressureϫ2)/3] by the flow at rest, and we calculated resistance at maximal vasodilation by dividing mean blood pressure by flow during hyperemia.
CFR was defined as a ratio of myocardial blood flow during adenosine to flow at rest.
Responders were defined as those with an increase in CFR during follow-up of Ͼ20% (cutoff threshold of 1 SD above mean of average CFR).
Quantitative Coronary Angiography
Coronary angiograms were analyzed by 3 cardiologists blinded to PET data.
Stenoses were quantified (percent luminal area stenosis) by use of an automated edge-contour detection system (Philips Integris H 3000, Automated Coronary Analysis version 1993 15 ). The degree of stenosis in each vessel territory was grouped as Ͻ25%, 26% to 50%, 51% to 75%, or 76% to 100% area stenosis of the vessel diameter. Only the most severe stenosis was used to represent each territory for statistical analysis.
Bicycle Exercise Testing
Patients exercised using a bicycle ergometer. The initial workload was 25 W and was increased in 25-W increments every 2 minutes. Exercise was discontinued when the subject developed dyspnea, anginal symptoms, leg fatigue, generalized fatigue, or occurrence of ST-segment depression Ͼ0.2 mV. The ECG was considered positive if horizontal or downsloping ST-segment depression Ͼ0.1 mV 0.08 seconds after the J point occurred.
Statistical Analysis
All values are expressed as meanϮSD.
Friedman test was used to compare the 3 time points, followed by Wilcoxon test in case of significance. Otherwise, the Mann-Whitney U test was used to compare 2 groups of continuous variables. All tests were 2-tailed. Spearman's correlation coefficients were calculated to study the associations between different variables. A value of PϽ0.05 was considered statistically significant.
Results
Patients
Of the 22 patients enrolled, 7 did not complete the study protocol. Four patients discontinued use of fluvastatin due to adverse effects (nightmare, skin rash, and gastrointestinal symptoms 2 ), and 3 declined follow-up. Fifteen patients (10 men, 5 women) successfully completed the protocol. Baseline characteristics and medication of individual patients are listed in Table 1 . All female patients were postmenopausal and did not receive hormonal substitution. During the follow-up period, patients did not change their use of concomitant medication. Neither of the 2 current smokers quit smoking.
Serum Lipid Profiles
Serum lipid profiles at baseline and during pharmacological intervention are summarized in Table 2 .
After 2 months, there was a significant decrease (PϽ0.05) in total cholesterol (29Ϯ6%), LDL (37Ϯ9%), and triglycerides (15Ϯ28%), with no further change at 6-month follow-up. Likewise, there was a significant reduction of the total cholesterol to HDL cholesterol ratio (29Ϯ14%) and the LDL to HDL cholesterol ratio (37Ϯ15%) after 2 months (PϽ0.05), with no further change after 6 months of therapy, whereas there were no significant changes of HDL cholesterol during the intervention period.
No significant differences in percent changes of the different cholesterol levels were found between patients receiving 60 (nϭ5) or 80 (nϭ10) mg of fluvastatin.
Hemodynamic Responses to Adenosine Infusion
Overall, there was no significant decrease in systolic or diastolic pressure, but heart rate and RPP increased significantly during infusion of adenosine (see Table 3 ). No significant changes in systolic or diastolic blood pressure were seen at rest or during adenosine infusion at baseline or after 2 or 6 months of follow-up. There were no significant differences in heart rate or RPP between baseline and follow-up studies. The increase in RPP was similar at baseline (36Ϯ33%), at 2 months (30Ϯ25%), and at 6 months (30Ϯ31%) (PϭNS).
Myocardial Blood Flow
Resting blood flow at baseline averaged 0.7Ϯ0.2 mL ⅐ g Ϫ1 ⅐ min Ϫ1 and remained unchanged at 2-month follow-up
; PϭNS). No statistically significant difference was seen at 6-month follow-up, with resting blood flow averaging 0.7Ϯ0.2 mL ⅐ g Ϫ1 ⅐ min Ϫ1 . Adenosineinduced hyperemic blood flow at baseline was 1.7Ϯ0.5 mL ⅐ g Ϫ1 ⅐ min Ϫ1 and remained unchanged at 2-month follow-up, averaging 1.7Ϯ0.5 mL ⅐ g Ϫ1 ⅐ min
Ϫ1
. A significant increase in hyperemic blood flow was obtained at 6-month follow-up, averaging 2.3Ϯ0.9 mL ⅐ g Ϫ1 ⅐ min Ϫ1 (PϽ0.05 versus baseline). Global CFR was similar at baseline (averaging 2.5Ϯ0.6) and at 2-month follow-up (averaging 2.7Ϯ0.9). At 6-month follow-up, CFR increased significantly by 38Ϯ41% to 3.4Ϯ1.0 (PϽ0.05 versus baseline) (Figure 2 ). When regional analysis of CFR at baseline was compared with the degree of the maximum stenosis of the territory, a significant negative correlation between percent stenosis and regional stress flow (rϭϪ0.39, PϽ0.05) and regional CFR (rϭϪ0.42, PϽ0.05) was found. No significant differences, however, were found between the 4 subgroups of segments in regional CFR or in the percent increase in coronary blood flow during the 6-month follow-up period (Table 4) . Moreover, percent changes in blood flow, resistance at rest and during adenosine infusion, and global CFR were not related to age, sex, hemodynamic parameters, or fluvastatin dose.
Nine patients fulfilled the criterion for responders (Ͼ20% increase in CFR). There was no statistical difference in age, sex, lipid levels at baseline, amount of lipid lowering during follow-up, other risk factors, or hemodynamic parameters between the 2 groups.
All responders quoted an improvement in anginal symptoms, whereas nonresponders stated no change (nϭ4) or worsening of anginal symptoms (nϭ2). However, no differences in exercise capacity or ST-segment depression were observed between the 2 groups.
Relationship Between CFR and Plasma Lipid Fractions
There was no significant relationship of CFR at baseline to total cholesterol, LDL, HDL, triglycerides, total cholesterol/ HDL ratio, or LDL/HDL ratio. No correlation existed between changes in lipid levels and changes in CFR in follow-up studies.
Relationship Between CFR and Age
There was a significant negative correlation between CFR and age (rϭϪ0.7, PϽ0.05). This was due to lower maximum flows in the older subjects (rϭϪ0.7, PϽ0.05), whereas no difference was observed for resting blood flow (rϭϪ0.1, Pϭ0.74). There was a significant correlation between age and resistance at maximum flow (rϭ0.89, PϽ0.05) and between age and percent change in resistance (rϭ0.78, PϽ0.05). No correlation was found between the adenosine-induced increase in the RPP and age.
Anginal Symptoms: Exercise Testing
At baseline, 2 patients had CCS III anginal symptoms, 8 were CCS II, and 5 were CCS I. During the follow-up period, anginal symptoms improved in 9 patients, 4 stated no improvement in symptoms, and 2 patients' symptoms were aggravated. At 6-month follow-up, 1 patient was in CCS III, 1 was in CCS II, and 13 were in CCS I.
All but 1 patient underwent a symptom-limited bicycle test. At baseline, 4 patients had a positive exercise test. Three of those developed significant ST depression. The average peak exercise workload achieved at baseline was 130Ϯ38 W, with an average duration of exercise of 10.0Ϯ3.0 minutes. The 
Influence of Gender
When men (nϭ10) and women (nϭ5) were compared, significant differences at baseline were found in total cholesterol levels (250Ϯ20 versus 276Ϯ24 mg/dL, respectively; PϽ0.05), HDL levels (48Ϯ11 versus 62Ϯ12 mg/dL, respectively; PϽ0.05) and triglycerides (175Ϯ62 versus 104Ϯ19 mg/dL, respectively; PϽ0.05). There was no difference in global CFR at baseline or at follow-up studies between men and women. Further analysis revealed no differences between these groups concerning percent changes in CFR, resistance at rest or stress, hemodynamic parameters, or percent changes of lipid levels, but there were differences in changes in triglyceride values (Ϫ25Ϯ22% for men versus 10Ϯ38% for women; PϽ0.05).
Discussion
These data demonstrate that lipid-lowering therapy with fluvastatin increases CFR in patients with hypercholesterolemia and CAD. Although there was a rapid decrease in LDL by Ͼ30% after 2 months of treatment, no significant change in CFR was observed at that time. Despite the absence of a further reduction in serum cholesterol levels, there was significant improvement in CFR after 6 months. The improvement in CFR resulted primarily from a decrease in vascular resistance during adenosine infusion, suggesting a beneficial effect of long-term lipid lowering on stressinduced flow capacity. Moreover, the improvement in CFR was associated with an improvement in anginal symptoms.
Baseline Study
At baseline, global CFR values of the studied patients with modest atherosclerotic lesions were lower than data reported for normal volunteers, whose coronary blood flow increases 3.5-to 5-fold during adenosine infusion, 9,11 and lower than reported for asymptomatic men with high risk for CAD (2.9Ϯ0.9). 10 Our finding of an inverse relation between the severity of coronary artery stenosis and CFR is consistent with previous studies 13,16 -19 that have demonstrated that basal flow is not impaired while maximum blood flow begins to decrease at 30% to 40% diameter stenoses. As in previous studies, there was substantial variability among patients with comparable severity of stenoses. This variability may be due to geometric complexity of stenoses, variations in extent and length of vessel involvement, variable collateralization, and endothelial dysfunction. 13, 16, 19 Previous studies in normal volunteers described an agerelated increase in resting blood flow, which was correlated with RPP, and a tendency toward lower hyperemic blood flows in older subjects. 20, 21 In contrast to these findings in normal subjects with low risk for CAD, the decrease in CFR in the present study was primarily determined by decreasing hyperemic blood flow. In this context, it is noteworthy that all studied patients had CAD and Ն1 risk factor, and all but 1 were older than 50 years.
Time-Course Effects of Lipid-Lowering Therapy
The onset and mechanisms of the therapeutic benefits of lipid-lowering therapy are not yet clearly understood. Because most clinical studies use only 1 time point to evaluate therapeutic effects, the aim of the present study was to define the time course of changes in the myocardial microcirculation in response to lipid-lowering therapy.
Previous data showed improvement in endotheliummediated vasodilator responses to acetylcholine in CAD patients by treatment with HMG-CoA reductase inhibitors with or without antioxidants after a period of 6 to 12 months. 5, 6 In atherosclerotic monkeys, dietary fat restriction has been shown to improve endothelial function within 4 to 18 months. 22, 23 In contrast to these animal studies, there are findings of fast improvement in endothelium-dependent vasomotor function in the human forearm within 2 to 12 weeks of lipid-lowering therapy 24, 25 or even after a single session of apheresis. 26 Semiquantitative PET studies have shown that lipid-lowering therapy improved stress-induced defect size and perfusion abnormalities in patients with stenoses Ͼ50% diameter as early as 3 months after onset of therapy. 8 However, the studied patient population included patients with advanced CAD resulting in extensive stress-induced perfusion abnormalities.
The present data document, for the first time, that functional improvement in myocardial perfusion as a marker for the microcirculatory reserve seems to be a slow process, which agrees with the observed time course of beneficial clinical results. The observed reduction in anginal symptoms underlines the clinical relevance of lipid-lowering therapy in our patient population, as has been shown in prior studies. 4 At baseline, patients' exercise capacities were not greatly affected by CAD. This is in contrast to the previous study by Czernin et al, 27 whose patients did not undergo cardiovascular conditioning as part of risk factor modification, which may explain the nonsignificant change in exercise capacity in their selected patients with only mild to moderate CAD.
In contrast to previous clinical trials suggesting an increasing benefit associated with longer treatment duration and larger reduction of LDL cholesterol, 1,2 improvement in flow reserve in the present study was not related to the amount of lipid lowering, nor were coronary flow or flow reserve at baseline significantly related to serum cholesterol concentrations. This discrepancy can be explained by the highly selected patient group with a narrow range of cholesterol levels and the definition of therapy response we used (Ͼ30% reduction of LDL cholesterol). Improvement in flow reserve was not related to the degree of stenoses, although baseline measurements were significantly correlated with the severity of stenoses. Quantitative flow measurements as used in the present study demonstrated a general improvement in CFR, even in territories with milder stenoses. This underlines the strength and sensitivity of quantitative flow measurements, because each vascular territory can be evaluated independently of control segments and directly compared with baseline results.
CFR did not normalize during the follow-up period, which is in concordance with previous investigations that indicated that lipid-lowering therapy did not completely restore endothelial function. 5, 6 Possible mechanisms underlying the improvement in hyperemic blood flow in the present study may include partial anatomic regression of atherosclerotic lesions and a beneficial effect on endothelium-dependent and -independent vasodilation. 8, 28 CFR as an integrating measure reflects vasomotor dysfunction. Because the pathophysiology is complex, it is difficult with existing in vivo methods to identify specific pathways by which improvement in vasomotor reactivity is achieved.
During therapy, patients could be separated into groups of responders and nonresponders. The decrease in anginal symptoms in responders was highly correlated with improvement in CFR. However, no differences in exercise capacity or ST depression were observed between the 2 groups. Furthermore, no significant differences between the tested variables could be found between the groups. Despite the small number of subjects studied, however, there was a trend to higher HDL cholesterol levels, higher HDL-dependent ratios at baseline, and greater extent of cholesterol lowering during therapy in responders. This suggests a possible relationship between improvement in CFR and these factors that may become significant in larger patient groups to be studied in the future.
When patients were followed up by questionnaire 1 year after termination of the present study, 1 of 6 nonresponders complained of further worsening of symptoms, 2 had been treated by CABG and 1 by PTCA in the interim because of angiographically documented disease progression, and another had died (sudden death). In contrast, only 1 of 9 responders had to be treated by PTCA, and 1 patient's symptoms worsened again, whereas 4 responders had stable improvement and 3 showed additional improvement in symptoms.
On the basis of these observations, one may speculate that PET flow measurements may be clinically useful in identifying nonresponders to lipid-lowering therapy and predicting adverse clinical outcome.
Limitations of the Study
The main emphasis of this study was to define the time course of changes in myocardial flow by a longitudinal study protocol. Because PET flow studies have been shown to be accurate and reproducible, 9 -13 the method appears appropriate for studying the effects of lipid-lowering therapy using patients as their own control subjects.
Patients continued taking their antianginal and antihypertensive medications, which were unchanged during the follow-up period. Nitrates, ␤-1 blockade, and calcium channel blockers have not been shown to significantly alter CFR. 29 ACE inhibitors were not used in our study population. Therefore, it is unlikely that the beneficial effects of lipidlowering therapy on CFR were due to other drug effects.
Clinical Implications
13 N-labeled ammonia PET studies have been shown to predict the functional significance of angiographically defined stenoses even in mild disease. Quantification of regional blood flow enables noninvasive monitoring of disease progression or regression with interventions such as lipid-lowering therapy. Additional studies in larger patient populations are needed to demonstrate the prognostic value of improved or unimproved CFR measures early after onset of therapy. According to our findings, this method may be useful in identifying nonresponders to HMG-CoA reductase inhibitor therapy, ie, patients with a rapidly progressive form of CAD, who may require close monitoring and aggressive therapy. The present data also indicate the importance of the time point in evaluating the effects of lipid-lowering therapy on myocardial blood flow, which needs to be considered in future protocol design.
